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Abstract
Background: Since its inception, the Uganda National Drug Authority (NDA) has regularly inspected private sector
pharmacies to monitor adherence to Good Pharmacy Practices (GPP). This study reports findings from the first public
facility inspections following an intervention (SPARS: Supervision, Performance Assessment, and Recognition Strategy)
to build GPP and medicines management capacity in the public sector.
Methods: The study includes 455 public facilities: 417 facilities were inspected after at least four SPARS visits by trained
managerial district staff (SPARS group), 38 before any exposure to SPARS. NDA inspectors measured 10 critical, 20 major,
and 37 minor GPP indicators in every facility and only accredited facilities that passed all 10 critical and failed no more
than 7 major indicators. Lack of compliance for a given indicator was defined as less than 75 % facilities passing that
indicator. We assessed factors associated with certification using logistic regression analysis and compared number of
failed indicators between the SPARS and comparative groups using two sample t-tests with equal or unequal variance.
Results: 57.4 % of inspected facilities obtained GPP certification: 57.1 % in the SPARS and 60.5 % in the comparative
group (Adj. OR = 0.91, 95 % CI 0.45–1.85, p = 0.802). Overall, facilities failed an average of 10 indicators. SPARS facilities
performed better than comparative facilities (9 (SD 6.1) vs. 13 (SD 7.7) failed indicators respectively; p= 0.017), and SPARS
supported facilities scored better on indicators covered by SPARS. For all indicators but one minor, performance in the
SPARS group was equal to or significantly better than in unsupervised facilities. Within the SPARS (intervention) group,
certified facilities had < 75 % compliance on 7 indicators (all minor), and uncertified facilities on 19 (4 critical, 2 major,
and 13 minor) indicators.
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Conclusions: Half of the Ugandan population obtains medicines from the public sector. Yet, we found only 3/5 of
inspected public health facilities meet GPP standards. SPARS facilities tended to perform better than unsupervised
facilities, substantiating the value of supporting supervision interventions in GPP areas that need strengthening.
None compliant indicators can be improved through practices and behavioral changes; some require infrastructure
investments. We conclude that regular NDA inspections of public sector pharmacies in conjunction with interventions
to improve GPP adherence can revolutionize patient care in Uganda.
Keywords: Pharmacy practices, Pharmacy inspection, Pharmacy certification, Medicines management, Supervision,
Pharmacy indicators, Public sector, Regulatory authority, Uganda
Background
Medicines are an essential and critical part of health care
services in all cultures and societies. To ensure that pa-
tients receive adequate care, it is imperative to provide
access to essential medicines and to trained health pro-
fessionals who manage, prescribe, and dispense medi-
cines appropriately.
In 1992, the first steps were taken to develop inter-
national standards for Good Pharmacy Practices (GPP)
with the latest revision jointly published in 2011 by the
International Pharmaceutical Federation and the World
Health Organization [1, 2]. GPP is defined as the prac-
tice of pharmacy that provides optimal, evidence-based
care for those who use pharmacists’ services [1, 2].
Several studies have found GPP implementation in
the private sector to be suboptimal, but few have in-
vestigated how GPP is implemented in the public sec-
tor [3–7]. A study comparing GPP implementation
between public and private pharmacies in Laos found
that both sectors performed poorly, and no differences
between sectors were observed in store management,
labeling, or patient counseling. The authors recom-
mended identifying interventions to improve phar-
macy practices [8].
Since its inception in 1993, the National Drug Author-
ity (NDA), an autonomous institution under Uganda’s
Ministry of Health (MoH), has been responsible for
ensuring that all medicines sold in Uganda are safe, ef-
fective, and handled in accordance to GPP standards.
The legal framework is the same for the public and pri-
vate sectors. It defines licensing and inspection, the
practice and scope of pharmacy as well as supply chain
integrity and medicines quality [9, 10].
In 2013, there were 604 licensed private sector phar-
macies and 6140 licensed drug shops [11, 12]. Private
facilities are regularly inspected by the NDA. Inspectors
use an indicator-based tool that measures the key areas
outlined in international GPP standards: suitability of
premises, quality of dispensing, store management, and
operating procedures. Until recently however, the NDA
did not inspect public sector facilities on a regular basis.
Instead, the MoH, district managers, and facility staff were
responsible for GPP implementation in the 2867 govern-
ment and 874 private not-for-profit (PNFP) facilities [11].
In Uganda, the public health sector is structured top-
down. At district level, it is divided into District Hospitals
(DH) and Health Centers (HC) IV, III, II, and I (i.e. Village
Health Teams). Higher level facilities – hospitals and HC
IV – have designated rooms for medicines storage and a
trained stores manager often manages supplies. Lower
level facilities – HCs II and III – often have only a cup-
board for storage, and the nursing officer is responsible
for all areas of management and use of medicines.
Close to half of Uganda’s population obtains their
medicines from public sector facilities [13]. Yet, several
constraints affect the quality of pharmacy services and
patient welfare in Uganda’s public health care system:
insufficient infrastructure, limited resources, poorly
trained pharmaceutical staff especially at district level,
and untrained medicines managers [11, 14, 15]. A 2012
national assessment of 3348 facility stores detailed severe
deficiencies in infrastructure, pharmaceutical manage-
ment tools, and storage facilities, including shelving.
Given these challenges, requiring public sector facilities
to meet the same practice and premises quality stan-
dards as the private sector has the potential to greatly
improve patient care in Uganda.
In 2012, the MoH initiated a national Supervision, Per-
formance Assessment, and Recognition Strategy (SPARS)
to increase capacity in medicines management and phar-
macy practices in the public sector, with the objective of
building a foundation towards GPP certification of all
public health care facilities [11, 16]. SPARS is based on
supportive supervision. Supervisors are public district staff
with formal training in medicines management including
a two-week classroom instruction followed by 5 days of
practical exercises. The role of supervisors is to visit
participating public health care facilities about every 2
months. At each visit, supervisors use a standard instru-
ment to measure the facility performance in five areas of
medicines management: prescribing, dispensing, reporting
and ordering, stores management, and stock management.
The SPARS instrument includes a total of 25 indicators,
4-7 in each area. All indicators are scored 0/1. The data
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collected is entered on- or of-line into a data base that has
inbuilt data checking and controls to clean and increase
data quality [17]. Many of the SPARS indicators are simi-
lar or partly similar to the GPP inspection indicators with
an indicator overlap of 73 %. During each visit, supervisors
also provide tools such as stock cards, stock books,
Uganda Clinical Guidelines, dispensing trays, dispensing
envelopes, thermometers, and the national standard oper-
ating procedures manual. SPARS was initially rolled out in
45 districts (40 %) in Uganda, with encouraging results:
after four SPARS visits, facilities achieved on average a
64 % improvement in medicines management and reached
a score of 17.4 out of 25 [11, 16, 18].
Along with building medicines management know-
ledge through SPARS, Uganda initiated GPP inspections
in the public sector to ensure equity of GPP implemen-
tation in the public and private sectors pharmacies. The
aims of this study were a) to assess adherence to GPP at
public health facilities in Uganda using results from the
first public sector GPP inspections carried out in the
country, and identify facility characteristics that influ-
ence GPP adherence and certification and b) to compare
GPP certification and indicator scores between SPARS-
supported facilities and unsupervised facilities.
Methods
Design and setting
The study is a cross-sectional, indicator-based comparison
of adherence to national GPP requirements between
SPARS-supported (intervention) and non-SPARS-supported
(comparative) government and private not for profit health
facility pharmacies in Uganda.
Sampling
All 45 SPARS-supported districts and five randomly
selected districts in the group of ten districts with no
SPARS support participated in the study. In the SPARS-
supported districts, facilities were considered ready for
NDA inspection after receiving at least four SPARS
supervisory visits. No other restrictions applied. The
SPARS strategy is a national strategy implemented in
102 (91 %) districts by implementing partners with only
ten districts not yet supported by SPARS limiting the
comparative districts.
Inspection tool
The tool in use for inspection of private pharmacies was
modified for the public sector to increase clarity and re-
producibility, and to address differences in staffing re-
quirements in public facilities due to the shortage of
pharmacists. Revisions were based on international GPP
standards, the WHO rational drug use indicators, and
SPARS indicators [1, 2, 5, 18, 19]. The revised tool was
finalized in April 2013 after being piloted in eight
inspections across two districts. The final tool applies
both retrospective and prospective data collection
through direct observations, record reviews, and ques-
tions. It includes 79 GPP indicators. Twelve indicators
record general administrative information about the
pharmacy, its ownership and staffing. The remaining 67
indicators are classified as critical (10), major (20), and
minor (37). They assess the premises (9 critical, 8
major, 12 minor), dispensing quality (1 critical, 4 major,
14 minor), stores management (7 major, 8 minor), and
operating requirements (1 major, 3 minor). 47 indica-
tors assess performance in either the store or the
dispensary, and 30 (45 %) assess performance at both
locations. The list of all assessed indicators, their classi-
fication, and overlap with SPARS indicators are pre-
sented in Additional file 1.
Similarities between the GPP inspection and SPARS
tools are inherent since SPARS aims to strengthen GPP
implementation. 49 (73 %) GPP indicators are similar to
SPARS indicators with 40 identical and 9 very similar in-
dicators. The overlap is highest in the areas of stores
management (93 %), premises (72 %), dispensing re-
quirements (63 %) and operating requirements (50 %).
Highest overlap of identical indicators is for major in-
dicators (18/20) (90 %), followed by critical indicators
(8/10) (80 %), and minor indicators with only (23/37)
62 % overlap.
Certification
To earn GPP certification, facilities must comply with all
critical indicators and not fail more than 7 major indica-
tors. If certified, the number and type of failed indica-
tors, if any, will determine the comments provided: no
comments, minor comments, or major comments. Certi-
fication with minor comments indicates that the facility
failed only minor indicators.
Data collection
Intervention facilities were inspected between May 2013
and March 2014 and comparative facilities between
January to March 2014. Inspections were planned in
rounds of eight inspections each covering a five-day
period. The NDA scheduled inspections according to
inspectors’ availability and planned district inspection
rounds. Forty-three trained and experienced national
drug inspectors undertook the inspections. In prepar-
ation, they received a one-day training session on using
the inspection tool and entering data electronically. They
were not informed if they inspected an intervention or
comparative district. They could not inspect their own
residential district. After data entry, inspection results
were uploaded to a central database and formed the
basis of automatically-generated inspection reports.
Eight inspectors surveyed both the comparative and
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intervention facilities. On average, they inspected 10
(range 1 to 37) intervention facilities and five (range 1 to
8) comparative facilities.
Data analysis
Health facility characteristics were compared between
facilities exposed to SPARS and those with no SPARS
exposure using the Pearson chi-square tests together
with Fisher’s exact tests. The proportions of facilities
earning certification by characteristics were calculated.
The association between certification status and health
facility characteristics was assessed using bivariate logis-
tic regression analysis to calculate odds ratios (ORs) and
95 % confidence intervals (CIs). Multivariable logistic re-
gression, considering characteristics that were significant
in the bivariate analysis, was used to estimate adjusted
ORs (Adj. ORs) and CIs. The proportion of facilities
passing each indicator was calculated and comparisons
made by health facility exposure to SPARS and compari-
son group not exposed to SPARS. The “compliance
score” was defined for each indicator as the percentage
of facilities receiving a ‘pass’, i.e., the percentage of com-
pliant facilities for that indicator. The Pearson chi-
square test together with Fisher’s exact test were further
used to assess the relationship between exposure to
SPARS and the compliance score. To determine if a re-
lationship existed, Simple Sequentially Rejective Mul-
tiple Test Procedure of adjusting the critical level was
used to account for multiple testing of all the indicators
[20]. The average number of indicators failed was cal-
culated and compared by exposure to SPARS. Two
sample t-tests with equal or unequal variances were
used to compare if the difference of average number of
failed indicators between the SPARS exposed and non-
SPARS exposed facilities across the four certification
categories (certified without comments, certified with
minor or major comments, not certified) were signifi-
cant. All statistical analyses were done using STATA
software version13.1.
Ethical considerations
The study is a retrospective analysis of data collected
under NDA legal requirement to implement GPP and
does not involve human subjects or data.
Results
Inspections were carried out in 493 facilities. A total of
38 inspections were excluded from the analysis as one or
more critical indicators were not recorded, leaving a
total of 455 inspections eligible for analysis of which 417
were in intervention and 38 in comparative facilities.
The intervention (SPARS-supported) inspected facilities
were comparable to the comparative facilities with
regards to ownership, and level of care. There were
regional differences between the intervention and com-
parative facilities with 60 % of the comparative facilities
being the in central region as compared to 32 % of the
intervention facilities in the same region (p < 0.001).
Comparative districts only represent three of the four
regions excluding the Eastern Region. See Table 1.
GPP certification and reasons for failure
Overall, the proportion of public health facilities
which obtained accreditation was 57.4 % (Table 2).
The percentage of certified SPARS-supported facilities
and comparative facilities was 57.1 and 60.5 % respect-
ively, this difference was not significant (Adj. OR =
0.91, 95 % CI 0.45–1.85, p = 0.802). The proportion of
certified PNFP facilities (58.3 %) was slightly higher
than that of government facilities (57.1 %) and the dif-
ference was not significant (Unadj. OR = 1.07, 95 % CI
0.64–1.81, p = 0.792). We found that facilities in the
Northern Region had significantly higher odds of cer-
tification compared to those in the Central region
(Adj. OR = 2.66, 95 % CI 1.54–4.61, p < 0.001). The
odds of certification of facilities in the Western and
Eastern regions were not significantly higher than
those in the Central region (Adj. OR = 1.16, 95 % CI
0.70–1.92 and Adj. OR = 0.67, 95 % CI 0.39–1.14
respectively).
Within the group of SPARS-supported facilities,
slightly more PNFP facilities were certified (58.3 %) than
government facilities (56.9 %), but the difference was not
significant (OR = 1.06, 95 % CI 0.61–1.85; p = 0.831).
Certification was significantly more frequent for hospi-
tals (89.5 %; Adj. OR = 8.92 95 % CI 1.97–40.51, p =
0.005) compared to HC IIs (52.5 %). Similar regional dif-
ferences in the proportion of certified facilities were
observed in this group; with facilities in the Northern re-
gion having significantly higher odds of certification
compared to those in the Central region (Adj. OR = 2.75,
95 % CI 1.53–4.93, p = 0.001).
Facilities cannot be certified if they fail any critical
indicator and over seven major indicators. Figure 1
displays the number of critical and major indicators
failed in the intervention and comparative facilities in-
cluding both certified and none certified. It shows that
fewer uncertified intervention facilities than uncerti-
fied comparative facilities failed two or more critical
and major indicators.
To identify areas of none compliant GPP implementa-
tion in the SPARS supported facilities (intervention), we
identified indicators failed by 25 % or more of the
inspected facilities and classify these areas as challenging
in regards to GPP implementation. Thus, if performance
for a given indicator was less than 75 % facilities passing
that indicator it fell within areas of challenge to GPP im-
plementation. Challenging areas were identified for 19
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(28 %) of the 67 indicators in the intervention group
(Fig. 2). challenging areas identified by critical indica-
tors covered: availability of hand washing facilities,
adherence to labeling requirements, and roof and
ceiling conditions. The challenging areas identified by
major indicators were: storage and recording of ex-
pired medicines. The remaining challenging areas fell
within the area measured by minor indicators that do not
influence certification. Certified facilities had challenging
GPP adherence areas identified by seven indicators (all
minor), and uncertified facilities by 19 (four critical, two
major, and 13 minor) indicators (Fig. 2).
The proportion of certified facilities passing each indi-
cator was higher than that of uncertified facilities, and
the differences were significant (p < adjusted 0.05) for 26
indicators (results not shown).
Table 1 Comparison of health facility characteristics of comparative and intervention groups
Reference Intervention Total p-value
# (%) # (%) # (%)
Number of facilities (#)/(%) 38 (8.4) 417 (91.6) 455 (100)
Ownership
Government 30 (78.9) 357 (85.6) 387 (85.1) 0.270
PNFP 8 (21.1) 60 (14.4) 68 (14.9) .
Level of care
Health Center II 16 (42.1) 217 (52.0) 233 (51.2) 0.258
Health Center III 14 (36.9) 149 (35.7) 163 (35.8)
Health Center IV 4 (10.5) 32 (7.7) 36 (7.9)
Hospital 4 (10.5) 19 (4.6) 23 (5.1)
Regions
Central 23 (60.5) 121 (29.0) 144 (31.6) <0.001
Northern 8 (21.1) 101 (24.2) 109 (24.0)
Western 7 (18.4) 102 (24.5) 109 (24.0)
Eastern 0 (0.0) 93 (22.3) 93 (20.4)
Table 2 Certification status and confidence interval by arm, ownership, level of care and regions for all facilities
No. certified/n (%) Unadj. OR (95 % CI) Adj. OR (95 % CI)
Total 261/455 (57.4)
Arm
Comparative 23/38 (60.5) 1.00 1.00
Intervention 238/417 (57.1) 0.87 (0.44–1.71) 0.91 (0.45–1.85)
Ownership
Government 203/387 (57.1) 1.00
PNFP 35/68 (58.3) 1.07 (0.64–1.81)
Level of care
Health Center II 125/233 (53.6) 1.00
Health Center III 98/163 (60.1) 1.30 (0.87–1.95)
Health Center IV 20/36 (55.6) 1.08 (0.53–2.19)
Hospital 18/23 (78.3) 3.11 (1.12–8.66)*
Region
Central 77/144 (53.5) 1.00 1.00
Northern 82/109 (75.2) 2.64 (1.53–4.55)** 2.66 (1.54–4.61)**
Western 62/109 (56.9) 1.14 (0.70–1.89) 1.16 (0.70–1.92)
Eastern 40/93 (43.0) 0.66 (0.39–1.11) 0.67 (0.39–1.14)
* p < 0.05, ** p < 0.001
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Impact of SPARS intervention
To investigate the impact of SPARS on GPP adherence,
we compared the number of failed GPP indicators as
well as certification status between SPARS-supported
and comparative facilities.
Effect of SPARS on compliance scores
Figure 3 shows that the group of SPARS-supported
facilities performed significantly better (p < adjusted 0.05)
than the comparative group in 3 of the 4 assessment areas
(dispensing requirements, stores management and prem-
ises) and for two categories of indicators (major, minor).
Overall, intervention facilities outperformed significantly
comparative facilities for 7 (10 %) indicators (I > Co), 59
(88 %) of the indicators (I = Co) did not differ, and
comparative facilities scored higher for 1 (2 %) indicators
(I < Co). SPARS-supported facilities outscored the com-
parative group on overlapping and none overlapping indi-
cators (12 % vs. 2 % and 6 % vs. 0 % respectively).
An additional file present the compliance score for
each indicator in the two arms [See Additional file 2].
Figure 4 depicts the eight indicators (7 with I > Co
and 1 with Co > I) with significantly different perform-
ance between intervention and comparative facilities.
Fig. 1 Comparison of intervention and comparative facilities by number of failed critical and major indicators
Fig. 2 GPP indicators (C = Critical, Ma =Major and M =Minor indicators) identifying areas with challenges in adhering to GPP requirements identified
by a indicator compliance score of below 75 % in SPARS-supported facilities, by certification status
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No significant differences were seen between the two
arms for any of the critical indicators of which one in-
dicator (labeling) is influenced through SPARS super-
vision. The intervention group scored higher for one
major and 6 minor indicators, and performed on aver-
age 30 % better than comparative facilities for these
indicators (range 20 to 55 %). The comparative group
scored higher for 1 minor indicator by 30 %.
Effect of SPARS on the number of failed indicators
Table 3 displays the average number of failed indicators
by certification status comparing intervention and com-
parison facilities. A perfect score is zero indicating all
GPP indicators passed. Comparative facilities failed more
indicators than intervention facilities, 13 versus 9 indica-
tors respectively (p = 0.017). Comparing facilities failing
certification showed that SPARS supported facilities
failed fewer indicators compared to the comparison fa-
cilities, 13 versus 18 (p = 0.003). On average, a certified
intervention facility failed 6 indicators (out of 67 indica-
tors), while a certified comparative facility failed 9 indi-
cators. For certified facilities the difference between
SPARS supported and comparative facilities were only
significant for certification with major comments, with
SPARS supported facilities failing 8 compared to 13 indi-
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Fig. 3 GPP indicator scores, by assessment area and by direction of significant differences between I (intervention - SPARS supported facilities)
and Co (comparative facilities)
Fig. 4 GPP indicators with significant differences in compliance score between intervention (SPARS supported) and comparative facilities. Indicators
classified as Major (Ma) and Minor (M). *Identify indicators that are different (no overlap) from SPARS indicators
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Discussion
Our study investigated adherence to GPP in the public
sector and the effect of a national capacity building strat-
egy SPARS on GPP implementation in Uganda, from
data collected during the first NDA inspections carried
out in the public sector.
Our study explored the adequacy of the redesigned
NDA inspection tool for assessing GPP implementation
in government facilities. The tool allowed collecting data
that can be used as baseline in future interventions. It
has formed the basis for developing strategies to im-
prove adherence to GPP requirements at facility level
and thereby increase GPP accreditation. In addition,
using the same tool to inspect government, PNFP, and
private sector pharmacies allows quantifying and com-
paring facility improvements and GPP accreditation sta-
tus over time and across sectors.
Appropriate data quality was ensured by selecting
experienced inspectors who were trained to use the elec-
tronic, standardized, and indicator-based inspection data
collection form. Completeness of data was occasionally
problematic, but the intervention sample was large
enough to allow for exclusion of facilities with incom-
plete data. The excluded facilities were similar to the in-
cluded in regards to level of care, ownership and region,
suggesting that exclusion would not influence the re-
sults. Continued training of inspectors is recommended.
Experience with electronic data entry combined with
the use of a central database was optimal in standardiz-
ing the assessment. Inspectors were able to enter data
while on site and see the results instantaneously: this
was critical to ensure data quality and completeness.
Electronic data entry is a solution to the increased
workload created by the increased number of inspec-
tions. Building additional features such as a spider
graph or histogram of inspection data for each facility
would undoubtedly help facilities visualize their GPP
status in real time and track improvements for their
staff [5, 7, 16].
Our results indicate that GPP are insufficiently imple-
mented in the public sector both at government as well as
PNFP sector facilities, a situation similar to that in Laos
[8]. Overall, only 57 % of public facilities met required
GPP standards and were certified to practice pharmacy.
Our study suggests the need to complement SPARS
interventions with inspections as a regulatory strategy to
continually monitor facilities’ progress [7, 21, 22].
Hospitals tended to outperform lower level of care fa-
cilities, possibly because certification rules favor better
equipped facilities: a facility obtains accreditation only if
it passes all critical indicators and all but one critical
indicator depend on building infrastructure. Ensuring
good performance in this area requires financial invest-
ments to implement infrastructural improvements re-
lated to roofing, walls, water and sanitation, and spacing.
Most other areas where GPP is found challenging can be
addressed by behavioral and procedural changes. The
relatively higher proportion of hospitals included in the
comparative group (10.5 %) than in the intervention
group (5 %) could have confounded these results as they
are generally better resourced. However, the certification
results and differences between groups did not change
after excluding all hospital level data from the analysis
(results not shown).
Similarly, one could have expected PNFP facilities to
outperform Government facilities because of donor and
patient funding sources. That however was not found,
possibly because the majority of the PNFP lower level
facilities are situated in most poor and rural settings
with low self financing and cost recovery capacity.
The Northern Region outperformed the other regions
with regards to GPP certification independent of expos-
ure to SPARS. SPARS implementation was also better in
this region, with no immediate explanation [17].
Table 3 GPP certification status: Average number of indicators failed in comparative and intervention facilities
Overall (n = 455) Intervention (n-417) Comparative (n = 38)
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Certification with
minor comment
126 4.19 (2.6) 3.74–4.64 115 4.08 (2.6) 3.60–4.56 11 5.36 (1.8) 4.23–6.50 0.116
Certification with
major comment
134 9.01 (5.1) 8.14–9.87 123 8.62 (4.8) 7.75–9.48 11 13.36 (5.7) 9.85–16.88 0.026
Certifieda 261 6.65 (4.7) 6.07–7.22 238 6.42 (4.5) 5.84–7.00 23 8.96 (6.0) 6.35–11.56 0.062
Failed GPP
certification
194 13.64 (6.0) 12.79–14.49 179 13.27 (5.8) 12.41–14.12 15 18.07 (6.8) 14.30–21.84 0.003
Totala 455 9.63 (6.3) 9.04–10.21 417 9.36 (6.1) 8.77–9.95 38 12.55 (7.7) 10.02–15.09 0.017
at-test with unequal variances; SD: standard deviation
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The stringent rule of certifying only facilities that pass
all critical indicators may also explain the lack of differ-
ence in certification between the two groups, even though
SPARS-supported facilities outperformed comparative fa-
cilities otherwise. The certified SPARS supported facilities
failed an average of six indicators compared to nine indi-
cators for comparative, and majority of them failed only
one critical and one major indicator compared to compar-
ative’s failing three or more critical and major indicators.
Another possible explanation for the lack of differ-
ence in certification is the size of the reference sample
which was considerably smaller than the intervention
group and for this reason probably not representative
even though it was comparable in terms of level of
care and type of facilities (government or PNFP). The
small number of the comparative sample reduces the
power of this study to find significant difference be-
tween intervention and comparative facilities. A com-
parative sample of 388 facilities would have been
necessary to detect a difference of 10 % between the
two arms with a power of 80 %.
Our study suggests the benefit of preparing facilities
for accreditation through a GPP strengthening strategy,
such as SPARS. SPARS-supported facilities performed
better than comparative facilities, had higher overall
GPP compliance score and outperformed the compara-
tive facilities in passing major, and minor indicators.
There was no difference in compliance score for critical
indicators between the two arms. One explanation could
be that critical indicators mainly assess structural condi-
tions, such as wall, floors, roofs, water and sanitation for
which supervision has limited influence. Further, of the
indicators in which intervention facilities outperformed
comparative facilities, all were indicators covered and
regularly monitored by the SPARS intervention except
for cleanliness of the counting tray that is not part of the
SPARS indicators or supervision. Shelving was provided
as part of SPARS, and most intervention facilities are
now able to store medicines in a more systematic and
organized manner, which underscores the considerable
impact of improving infrastructure. Comparative facil-
ities outperformed intervention facilities for one indi-
cator covered by the SPARS intervention: patient
knowledge, an indicator that much depends on avail-
ability of dispensing envelopes known to frequently be
out of stock at lower level facilities.
SPARS and GPP focus areas overlap in 49 (73 %) of
the indicators. These areas are stores management,
premises management, and dispensing, with little over-
lap in operating requirements. These areas and indica-
tors of overlap are correlated with the intervention
group’s higher performance scores. However, interven-
tion facilities only outperformed comparative facilities
in 6 (12 %) of the 49 overlapping indicators. Most of
the other 43 overlapping indicators were already well
implemented before the study, explaining why 27
(63 %) of them scored above 85 % in both groups, decreas-
ing the chance to observe any difference. Though SPARS
indicators assess GPP implementation and identify deficien-
cies, resource allocation is management responsibility and
SPARS strategy is limited to inexpensive corrective actions
through in service training and behavior change. Moreover,
there is still room for improvement after four SPARS visits.
The main limitation of the study is its cross sectional de-
sign and the related inability to demonstrate overtime im-
provement in SPARS-supported facilities compared to
comparative. In addition, the GPP certification imple-
mented as a national strategy made it not possible to have
an equal sized comparative sample. All NDA inspectors
have performed GPP inspections over the past many years
using an almost similar tool and there is no reason to ex-
pect differences in the inspection outcome related to the
time of inspection in the study period. One could expect
inter-rater viability between the inspectors, however this
was not investigated (Blick B, Nakabugo S, Seru M, Trap B.
Evaluating inter-rater reliability of indicators to assess
Ugandan health facility performance in medicines manage-
ment. Unpublished). The exclusion of 38 facilities due to
incomplete data for at least one critical indicator is unlikely
to have influenced the results: these facilities did not differ
from those included in the analysis with regards to level of
care, region, ownership, and exposure to SPARS. Finally,
the differences between SPARS and certification indicators
created analytical challenges in testing the relationship
between SPARS and GPP certification.
Conclusion
Our study documents the need for establishing regular
GPP inspections in the public sector as only 57 % of
public sector facilities meet GPP certification criteria.
Generally, GPP is insufficiently implemented in govern-
ment and private not-for-profit facilities.
Our results suggest the value of preparing facilities for ac-
creditation through a GPP-strengthening strategy. Specific-
ally, SPARS-supported facilities had better overall GPP
implementation across all categories of indicators (critical,
major, and minor). Higher performance was most pro-
nounced in GPP areas supported by SPARS supervision. A
capacity building strategy, such as SPARS, combined with a
regulatory intervention, such as GPP inspections and infra-
structural development, are important instruments to im-
prove GPP implementation and equity in Uganda.
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